Cannabis Investing News
See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments
Elixinol Global confirmed the non-compliant sale of its hemp-derived CBD products by its subsidiary Elixinol Japan.
Elixinol Global (ASX:EXL,OTCQX:ELLXF) confirmed the non-compliant sale of its hemp-derived cannabidiol (CBD) products by its subsidiary Elixinol Japan.
As quoted in the press release:
The breach was discovered internally following the recent review of each global business unit’s operations. The Company takes its compliance with all legislation and regulations seriously and is conducting an investigation into the circumstances of the non-compliance in relation to the hemp-derived CBD business unit within Elixinol Japan.
The non-compliance relates to the strict requirements in Japan on sourcing CBD from only hemp stalk and seed. The Company expects that the investigation (which involves an independent legal expert) will be completed by mid-November 2019.
The Company increased its ownership in Elixinol Japan from 10 percent to 50.5 percent for A$2.2 million in September 2018.
Top News
FEATURED STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.